The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.
August 11th 2025
Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.
August 8th 2025
Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.
August 3rd 2025
The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.
August 2nd 2025
Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.
July 31st 2025
Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.
July 30th 2025
John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.
July 29th 2025
John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.
Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.
Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.
John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.
July 25th 2025
Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.
Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.
July 24th 2025
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.
July 22nd 2025
Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.
Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.
Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.
July 19th 2025
Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.
July 18th 2025
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
July 16th 2025
Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.
July 15th 2025
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.